Jefferies Reiterates Buy Rating on Neurocrine Bio. (NBIX)

December 17, 2025 4:27 AM EST Send to a Friend
Jefferies analyst Akash Tewari reiterated a Buy rating and $174.00 price target on Neurocrine Bio. (NASDAQ: NBIX)The analyst comments "NBIX ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login